May 9, 2022
  • A study published in JAMA Health Forum found that prescription drug rebates from drugmakers to commercial health plans are steadily increasing. However, while such rebates can reduce plans’ net costs, they do not reduce patients’ cost sharing. According to the authors, the current system creates an equity issue, particularly for patients buying individual plans. “We have the sick people paying more than their fair share for the drug and the rebate goes back to the plan to reduce premiums for the healthy,” one stated. (Study here)